MicroRNA-146a Contributes to SCI Recovery via Regulating TRAF6 and IRAK1 Expression

Jinsong Wei,1 Jiafeng Wang,2 Yulan Zhou,2 Shouquan Yan,2 Keshen Li,3,4 and Hongsheng Lin1

1Department of Orthopedics, The First Affiliated Hospital of Jinan University, Guangzhou, China
2Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
3Institute of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
4Stroke Center, Neurology & Neurosurgery Division, The Clinical Medicine Research Institute and The First Affiliated Hospital of Jinan University, Guangzhou, China

Correspondence should be addressed to Keshen Li; likeshen1971@jnu.edu.cn and Hongsheng Lin; tlinhsh@jnu.edu.cn

Received 1 July 2016; Revised 27 July 2016; Accepted 11 August 2016

Academic Editor: Hai-Feng Pan

Copyright © 2016 Jinsong Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

MicroRNA-146a participates in spinal cord injury (SCI) recovery. Until recently, how miRNA-146a participates in SCI remained unclear. In this study, we tried to explore the roles of miRNA-146a in the recovery of SCI using a rat model. The expression of the probable target genes of miRNA-146a (including IRAK1 and TARF6) as well as proinflammation cytokines were measured until 7 days after surgery in the three groups (sham group, SCI group, and miRNA-146a antagomir injection group). Also, the animals’ motivations were estimated using Basso Beattie Bresnahan (BBB) during the whole experiment. A luciferase assay was performed to demonstrate that miRNA-146a could directly target the mRNAs of IRAK1 and TRAF6. Our experiments indicate that miRNA-146a inhibits proinflammatory cytokine secretion by suppressing IRAK1 and TRAF6 expression in the SCI model. In contrast, miRNA-146a may be upregulated by inflammatory mediators via the IRAK1/TRAF6 pathway in the spinal cord. As a negative feedback element, miRNA-146a could make sure that the expression of IRAK1- and TRAF6-mediated genes was under tight control. Thus, miRNA-146a may serve as a novel therapeutic target for SCI interventions.

1. Introduction

Spinal cord injury (SCI) is one of the most common injuries that is observed in spine and neurosurgery departments. The spinal cord is very susceptible to injuries and its self-repair capacity is limited. SCI is usually caused by sports injuries, building accidents, motor vehicle accidents, and violence. SCI can cause paralysis or loss of movement or sensation. Currently, the treatment of SCI remains one of the greatest challenges for clinical investigators, and the understanding of mechanisms that can be utilized by SCI therapeutics is still limited.

Biochemical disturbances accompany vascular alterations and cellular responses that are caused by SCI which will activate the inflammatory response. After that, cell apoptosis, Wallerian degeneration, and scarring will occur from days to years after the injury [1, 2].

Other investigators have previously reported that different gene expression along with posttranscriptional regulation significantly contributes to SCI pathogenesis [1, 3, 4]. Meanwhile, miRNAs have recently become the most important posttranscriptional regulators due to their ability to inhibit mRNA translation [5]. miRNA is a kind of noncoding small RNA, which is usually no longer than 22 nucleotides. The miRNAs are able to regulate gene expression by destabilizing mRNA translation [6, 7]. Individual miRNAs may affect a biological process by coordinating the translation of several even dozens of coding genes [8].

More and more evidence that miRNAs are involved in immune response have been found in recent studies [9, 10]. Furthermore, there is now accumulating evidence suggesting that miRNA-146a participates in the regulation of the innate immune response, which is well known for its regulation of
the TLR signaling pathway and proinflammatory cytokines [11–13]. miRNA-146a has been certified to downregulate its target genes TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1), which leads to the inhibition of the inflammatory reaction in macrophages, monocytes, astrocytes, and neurons [14–17]. Also, Lu et al. [18] demonstrated that miRNA-146a could attenuate neuropathic pain by suppressing TRAF6 signaling in the spinal cord.

Preliminary studies using next generation sequencing (NGS) examined the miRNA expression profiles post-SCI in animal models. Increasing expression of miRNA-146a was found in animal SCI models [5, 8]. Another study examined miRNA expression profiles post-SCI in rats using microarrays [19], which confirmed that there were significant and common changes in miRNA-146a expression. However, there is currently limited information regarding the role of miRNA-146a and its mechanism of action. The putative role of miRNA-146a in SCI is still based on in silico predictions, and no direct evidence is reported. How miRNA-146a modulates the downstream target genes in SCI is still unknown, given that TRAF6 and IRAK1 play an important role in neuroinflammation [20, 21], and miRNA-146a acts as a key regulator of the inflammatory reaction [15, 16]. In this study, we determined the role of miRNA-146a in SCI and tried to find out how it participated in SCI recovery by regulating its target genes (TRAF6 and IRAK1) using a rat SCI model.

2. Material and Methods

2.1. Animals Used. Adult, female Wistar rats weighing approximately 200 g obtained from the Laboratory Animal Center of Guangdong Medical University (Guangdong, China) were used for all experimental procedures. The rats were housed in wire cages (50 × 30 × 20 cm) with food and water continuously available.

2.2. SCI Model and Treatment. A rat SCI model was established by compressing the spinal cord using a forceps with a preestablished separation of the blades for 10 sec (approximately 200 kdyne, which was determined by preliminary experiments) at the 8–10th thoracic vertebra to induce a spinal cord injury. Forceps blade separation was confirmed before each surgery with microcalipers making sure that the dura remained intact during injury introduction. After compressing, the injury site was washed with room temperature saline. Most SCI rats exhibited flaccid paralysis or spasm of the lower extremities after the SCI surgery. In our study, the rats that exhibited flaccid paralysis of the lower extremities were chosen for the next study. The rats' bladders were manually expressed to assist urination twice a day until the animals regained bladder control. The injured animals were evaluated for lower extremities locomotion using BBB scale.

After SCI surgery, the rats were divided into 3 distinct groups: one group was injected with miRNA-146a antagonim negative control (SCI + NC), one group was injected with miRNA-146a antagonim (SCI + antagonim), and the last group was given laminectomies without the injection (sham). The tail intravenous injection was used for all the animal injections. After surgery, the rats were housed individually, and long sipper tubes were used to make sure that the rats could reach the water freely. The animals were anesthetized with an intraperitoneal injection of 7% chloral hydrate at 75 mg/kg before the animals were sacrificed.

2.3. RNA and Protein Extraction. Spinal cord fragments around the injury were cut out from the vertebra after the rats were sacrificed. Then, the fragments were maintained in RNAlater buffer (Qiagen) until total RNA extraction. Another group of animals treated in parallel was used for histopathology.

Total RNA was extracted by SV Total RNA Isolation Kit (Promega USA), and the concentration and purity were determined using a Nanodrop2000 spectrophotometer. RNA integrity was determined using agarose gel electrophoresis.

2.4. miRNA-146a Inhibition. MicrOFF™ mmu-miRNA-146a antagonim (RIBOBIO, Guangzhou, China) acted as a high-efficiency antagonist for miRNA-146a and was used for inhibiting the expression of miRNA-146a. Because the efficacy of the antagonim produced by RIBOBIO can last for two weeks in animal bodies, antagonim (5 nmol) was injected into animal bodies through the tail vein to avoid the extra injury from intrathecal injection on day 1, day 3, and day 5 after surgery. The time axis of injection and animal sacrifice are illustrated in Figure 1.

2.5. Real-Time Quantitative PCR (qPCR) and WB (Target Genes). MRNA reverse transcription was performed using an oligo dT primer and MMLV enzyme according to the manufacturer’s protocol. A small RNA extraction kit (Takara) was used for miRNA detection, and the small RNA reverse transcription was performed using PrimeScript miRNA cDNA Synthesis Kit (Takara). Real-time quantitative PCR analysis was performed using LightCycler® 480(Roche) with SYBR green dye detection (Takara). The primers used in our study were summarized as shown in Table 1.

Thermal cycle of qPCR amplifications was performed at 95 °C for 1 min, followed by 40 cycles at 95 °C for 5 s and 60 °C for 45 s, and a 10 min incubation at 72 °C was carried out at the end of the cycles. GAPDH and U6 were adopted as endogenous controls to normalize differences for mRNA and miRNA detection, respectively. Quantification analysis using
Table 1: Primers used in the study.

| Primer       | Sequence                  |
|--------------|---------------------------|
| TRAF6 forward| TCATTATGATCTGGACTGCGCAAC  |
| TRAF6 reverse| TGCAAGTGTCGTGCCAAGTG      |
| IRAK1 forward| GCCCGAGGAGTACATCAAGA      |
| IRAK1 reverse| CTCTGACCAGCCAAGGTCTC      |
| GAPDH forward| TGGTTCCTACCCCCAATGTG      |
| GAPDH reverse| GTGTAGCCCAAGATGCCCT       |
| miR-146a-5p forward| TGAGAACTGAATTCCATGGGT |
| U6 forward | GCTTCGGCAGCACATATACTAA |
| U6 reverse | CGAATTTGCGTGTCATCCTT |

normalizing cycle threshold values (Ct) with GAPDH Ct or U6 Ct and the data was analyzed using the 2^(-ΔΔCt) method. Melt curves were also performed after the amplification to avoid nonspecific products.

The protein concentrations were determined using a BCA protein assay kit (Shanghai, China) after the spinal cord was harvested. Western blotting analyses were performed using SDS-PAGE. After PAGE, the proteins were transferred to PVDF membranes. Then, the membranes were blocked in 5% nonfat milk for 1.2 h at room temperature and then incubated with antibodies overnight at 4°C. Antibodies against IRAK1 and TRAF6 were obtained from PL Laboratories (Canada), and the antibody against β-actin was purchased from Sigma. Proteins were visualized with enhanced chemiluminescence. Relative intensities were determined using Quantity One 4.6.2 software (Bio-Rad, USA), and GAPDH was used as the internal control. Data were given as the mean ± SD of the percentage ratio of the control.

2.6. Cytokines Detection. The inflammatory cytokines (including TNF-α, IL-1β, IL-6, IL-12, and RANTES) levels were determined to examine the effects of miRNA-146a on the levels of cytokines at the injured region. Spinal cord sample around the injury site was dissected and incubated in cell medium DMEM (Sigma) supplemented with 10% FBS and 0.2% paramucin. Inflammatory cytokines were detected after a 24 h incubation using a milliplex inflammatory cytokine kit (Millipore, USA). The cytokines were incubated with the antibodies in Elisa plates, after washing the extra antibodies, the absorbance was measured using a multiscan spectrum.

2.7. Luciferase Assay. In order to confirm whether miRNA-146a could directly target the mRNAs of IRAK1 and TRAF6, the 3'UTR sequence of IRAK1 and TRAF6 was cloned into the 3' site of the luc2 reporter gene on a plasmid (Promega, USA) to construct a report plasmid. Then, 300 ng of the plasmid, 30 ng of pRL-TK–Renilla luciferase, and the miRNA mimic (final concentration 40 nM) were cotransfected in SH-SY5Y using Lipofectamine 2000. Luciferase activity was measured by the Dual-Luciferase Reporter Assay (Promega) according to the manufacturer's protocol 24 hours after transfection.

2.8. Recovery of SCI and BBB. The animals were acclimated to the outside fields for 3 days before surgery to avoid subjects holding still (i.e., freezing) when they are introduced to a new apparatus. The BBB scale [22] was used for assessing locomotor behavior for 7 days after surgery in an open enclosure. Each animal was placed alone in the open field for 5 min, and locomotor behavior scores were derived according to the procedure developed by Basso et al. [22], making sure that the investigators’ scoring behavior had high intra- and interobserver reliability, and the person that provided the score was blind to the subject’s experimental treatment. All the scores were acquired three times to make sure the data were accurate.

2.9. Statistical Analysis. The results represent the mean ± standard deviation (SD). Differences in the data were tested for statistical significance using two-way ANOVA or one-way ANOVA. For all tests, $P < 0.05$ was considered to be statistically significant.

3. Results

3.1. Overexpression of miRNA-146a in the Animal Model of SCI. In the negative control (SCI + NC) group, miRNA-146a was increased ($P < 0.05$), whereas it was obviously downregulated after the miRNA-146a antagonim injection on the third and seventh day after surgery (Figure 2). Remarkable upregulation of miRNA-146a was not detected on the first day after surgery in the SCI + NC group, and also there was no difference in the expression of miRNA-146a during the experiment in the sham group (Figure 2).
Figure 3: mRNA levels of the target genes in different model groups. (a) TRAF6 mRNA levels and (b) IRAK1 mRNA levels. Three replications in each treatment of each time point; the average expression level was adopted.

Figure 4: Protein levels of the target genes in different model groups 7 days after SCI. (a) TRAF6 protein levels and (b) IRAK1 protein levels. Three replications in each treatment of each time point; the average expression level was adopted; * denotes the significant difference, \( P < 0.05 \).

3.2. IRAK1 and TRAF6 Were Regulated by miRNA-146a. Compared to miRNA-146a, the expression of genes IRAK1 and TRAF6 presented the opposite regulation model (Figure 3). The transcription of the two genes was increased on the first day after surgery and then decreased significantly over the next couple of days in the SCI + NC group. However, in the SCI + antagomir injection group, there was a dramatic upregulation of IRAK1 and TRAF6 in mRNA transcription on days 3 and 7 after SCI. Similarly, significant protein levels of the two genes were also detected and rose significantly in the antagomir injection group compared to the sham or SCI + NC group 7 days after the operation (Figure 4).
In order to detect a direct interaction between miRNA-146a and the IRAK1/TRAF6 3'-UTR, we, respectively, cloned the IRAK1/TRAF6 3'-UTR sequence downstream of the luciferase reporter gene. In the luciferase assay, the miRNA-146a mimics reduced the luciferase levels in the UTR-containing plasmids compared to the control group (\( P < 0.05 \); Figure 5). These results suggested that miRNA-146a may modulate IRAK1 and TRAF6 expression by directly targeting the 3'-UTR of their mRNA.

3.3. Expression of Proinflammatory Cytokines. Compared to the sham animals, the proinflammatory cytokines, such as IL-1, IL-6, IL-8, TNF-\( \alpha \), and RANTES, were increased on the first day after SCI surgery but reduced 3 or 7 days after SCI (SCI + NC). However, the proinflammatory cytokines kept increasing when the animals were injected with miRNA-146a antagonir (SCI + antagonir) (\( P < 0.05 \), Figure 6). In this sense, inhibition of miRNA-146a could positively regulate proinflammatory cytokines in the rat SCI model.

3.4. Recovery of SCI and BBB. The BBB scores showed that athletic ability was recovered in all the sham animals 3 days after SCI surgery. However, animals in the SCI + NC group recovered slowly compared to the sham group, and they regained athletic ability 7 days after SCI. Animals in the SCI + antagonir group endured more during the experiment, and even on day 7, the BBB scores were only approximately 5~10. Additionally, one of the animals in the antagonir group died on the 5th day after SCI surgery (Figure 7).

4. Discussion

Accumulating evidence suggests that miRNA-146a acts as a modulator of the innate immune response and affects the inflammatory cytokine levels in immunological and other brain cell types. Lukiw recently reported that an upregulated miRNA-146a might be integral to innate immune or inflammatory brain cell responses in prion-mediated infections and to progressive and irreversible neurodegeneration of both the murine and human brain [23]. Although accumulated evidence suggests that miRNA-146a may participate in SCI
recovery [5, 8, 24], there is still limited knowledge of the miRNA-146a regulatory networks that modulate genes expression.

IRAK1 and TRAF6 are known to be part of the common signaling pathway of the TIR super family, and they are also involved in the MAPK pathway. However, although several studies have reported that IRAK1 and TRAF6 were downregulated following miRNA-146a overexpression [14–18], the overexpression did not appear to be responsible for the responses that were observed following SCI recovery.

In our study, we found that IRAK1 and TRAF6 transcription in the SCI + NC group was upregulated on the first day after surgery compared to the sham group and then that transcription was significantly downregulated 3 and 7 days after the surgery (Figure 3). Similarly, the secretion of proinflammatory cytokines, including IL-6, IL-8, TNF-α, and RANTES, was extremely upregulated on the first day after surgery, whereas their expression was significantly downregulated 3 and 7 days after surgery in the SCI + NC group. Furthermore, the secretions of proinflammatory cytokines, as well as the protein levels of the two genes, rose sharply after antagonim was injected into the animals (Figures 4 and 6). Conversely, miRNA-146a expression was upregulated 3 and 7 days after surgery, whereas no remarkable expression differences were observed on the first day after surgery (Figure 2) in the SCI + NC group. Our data suggested that miRNA-146a played a repressive role in IRAK1 and TRAF6 expression and subsequently downregulated proinflammatory cytokines. This outcome was consistent with a former study that reported that miRNA-146a inhibited the expression of NF-κB [25] and the expression of some other inflammatory mediators, including TNF-α, IL-6, COX-2, and CXCL12 [15, 26, 27], which suggests an anti-inflammatory effect for miRNA-146a.

Moreover, the former study indicated that miRNA-146a negatively regulated the inflammatory response in human gingival fibroblasts by directly binding to the IRAK1 3’-UTR [28]. Also, the bioinformatic analysis exhibited that there are binding sites in the TRAF6 3’ UTR. Our luciferase assay also indicated that miRNA-146a could repress luciferase expression to directly target the 3’ UTR of TRAF6 and IRAK1 (Figure 5). Furthermore, the expression of TRAF6 and IRAK1 rose sharply after antagonim was injected into the animal model. Therefore, we speculated that miRNA-146a suppressed the expression of TRAF6 and IRAK1 via binding to the 3’ UTR. Consistent with this outcome, our data demonstrated that miRNA-146a could suppress the inflammation induced by SCI through downregulating IRAK1 and TRAF6.

The inflammatory response is usually modulated by molecular immune mediators, such as inflammatory cytokines (TNF-α, IL-6, etc.). Usually, excess proinflammatory cytokines would enhance the inflammation signaling pathway and induce more proinflammatory cytokines. This increase would initiate a vicious feedback loop that may play important roles in inducing or maintaining long-term inflammation (Figure 8).

However, our present data showed that SCI did not change miRNA-146a expression in the early phase (1 day), but the expression of miRNA-146a significantly increased in the maintenance phase (3 and 7 days). This result implied that the upregulation of miRNA-146a might be activated by proinflammation cytokines. In fact, Nakasa et al. [29] reported that TNFα and IL-1β could induce miRNA-146a expression in human rheumatoid arthritis synovial fibroblasts. Taganov et al. have also shown that miRNA-146a can be induced by NF-κB activation [16].

Furthermore, Xie et al. reported that miRNA-146a, IL-1, IL-6, and TNF-α levels were downregulated when inhibiting NF-κB. But, on the contrary, p50/p65 strongly activated the miRNA-146a promoter in a luciferase assay [30]. Wang et al. [17] found that intrathecal injection of amiRNA-146a mimic might exert antinociceptive effects by regulating the TRAF6 and IRAKI function in the DRG.

Therefore, we speculated that miRNA-146a could not only contribute to SCI recovery through inhibition of the IRAKI/TRAF6 pathway but also could be induced by proinflammatory cytokines downstream of the IRAKI/TRAF6 signaling pathway (Figure 8). This feedback mechanism provided an efficient way to avoid the severe inflammatory response induced by SCI, which contributed to the recovery of SCI.

These findings collectively indicate that miRNA-146a upregulation in SCI may be driven by proinflammatory cytokines, which in turn negatively regulate the proinflammatory cytokines by downregulating the expression of TRAF6 and IRAKI [31]. Thus, overexpression of miRNA-146a at 7 days after surgery for SCI may be a consequence of an increase in proinflammatory cytokines on previous time (1 day). Then the upregulation of miRNA-146a may have in turn inactivated this pathway via a negative feedback mechanism so that the IRAKI/TRAF6 pathway would not be overactivated. Therefore, miRNA-146a may serve as a powerful potential therapeutic target for SCI. However, we did not test whether an overdose of miR-146a mimic could improve the motor function after SCI, as the miRNA-146a level was already greatly upregulated (about 4 times), and

---

**Figure 8:** Schematic of miR-146a regulating inflammation by a negative feedback mechanism in the SCI.

---
the extra overdose of miR-146a mimic would overaffect the inflammatory reaction, which may be possibly harmful to the SCI recovery. But we do not disavow the possibility that overdose of miR-146a mimic may improve the motor function after SCI, which should be certified by further experiment.

Competing Interests
The authors declare that there is no conflict of interests regarding the publication of the paper.

Authors’ Contributions
Jinsong Wei and Jiafeng Wang contributed equally to this work.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (81471294, 81271213, and 81600445), the Natural Science Foundation of Guangdong Province (no. 2014A030313357), the Development Center for Medical Science and Technology, the National Health and Family Planning Commission of the People's Republic of China (no. W2013ZT083), and Scientific Fund of the No. 1 School of Clinical Medicine at Jinan University (no. 2015202).

References
[1] F. M. Bareyre and M. E. Schwab, “Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays,” Trends in Neurosciences, vol. 26, no. 10, pp. 555–563, 2003.
[2] C. Profyris, S. S. Cheema, D. Zang, M. F. Azari, K. Boyle, and S. Petratos, “Degenerative and regenerative mechanisms governing spinal cord injury,” Neurobiology of Disease, vol. 15, no. 3, pp. 415–436, 2004.
[3] O. Nesic, N. M. Srivakic, G.-Y. Xu et al., “DNA microarray analysis of the contused spinal cord: effect of NMDA receptor inhibition,” Journal of Neuroscience Research, vol. 68, no. 4, pp. 406–423, 2002.
[4] A. De Biase, S. M. Knoblach, S. Di Giovanni et al., “Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity,” Physiological Genomics, vol. 22, no. 3, pp. 368–381, 2005.
[5] M. Yunta, M. Nieto-Díaz, F. J. Esteban et al., “MicroRNA dysregulation in the spinal cord following traumatic injury,” PLoS ONE, vol. 7, no. 4, article e34534, 2012.
[6] I. Alvarez-Garcia and E. A. Miska, “MicroRNA functions in animal development and human disease,” Development, vol. 132, no. 21, pp. 4653–4662, 2005.
[7] P. D. Zamore and B. Haley, “Ribo-gnome: the big world of small RNAs,” Science, vol. 309, no. 5740, pp. 1519–1524, 2005.
[8] E. R. Strickland, M. A. Hook, S. Balaraman, J. R. Huiie, J. W. Grau, and R. C. Miranda, “MicroRNA dysregulation following spinal cord contusion: implications for neural plasticity and repair,” Neuroscience, vol. 186, pp. 146–160, 2011.
[9] M. A. Lindsay, “microRNAs and the immune response,” Trends in Immunology, vol. 29, no. 7, pp. 343–351, 2008.
[10] E. Sonkoly and A. Pivarcsi, “microRNAs in inflammation,” International Reviews of Immunology, vol. 28, no. 6, pp. 535–561, 2009.
[11] K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006.
[12] J. G. Cui, Y. Y. Li, Y. Zhao, S. Bhattacharjee, and W. J. Lukiw, “Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by miRNA-146a and NF-kB in stressed human astroglial cells and in Alzheimer disease,” The Journal of Biological Chemistry, vol. 285, no. 50, pp. 38951–38960, 2010.
[13] W. J. Lukiw, Y. Zhao, and G. C. Jian, “An NF-kB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells,” The Journal of Biological Chemistry, vol. 283, no. 46, pp. 31315–31322, 2008.
[14] J. Hou, P. Wang, L. Lin et al., “MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2,” The Journal of Immunology, vol. 183, no. 3, pp. 2150–2158, 2009.
[15] A. Iyer, E. Zurolo, A. Prabowo et al., “MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response,” PLoS ONE, vol. 7, no. 9, article e47899, 2012.
[16] K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore,”NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006.
[17] L. Wang, M. Chopp, A. Szalad et al., “The role of miR-146a in dorsal root ganglia neurons of experimental diabetic peripheral neuropathy,” Neuroscience, vol. 259, pp. 155–163, 2014.
[18] Y. Lu, D.-L. Cao, B.-C. Jiang, T. Yang, and Y.-J. Gao, “MicroRNA-146a-5p attenuates neuropathic pain via suppressing TRAF6 signaling in the spinal cord,” Brain, Behavior, and Immunity, vol. 49, pp. 119–129, 2015.
[19] N.-K. Liu, X.-F. Wang, Q.-B. Lu, and X.-M. Xu, “Altered microRNA expression following traumatic spinal cord injury,” Experimental Neurology, vol. 219, no. 2, pp. 424–429, 2009.
[20] Y. Lu, B.-C. Jiang, D.-L. Cao et al., “TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling,” Pain, vol. 155, no. 12, pp. 2618–2629, 2014.
[21] Y. Y. Li, J. G. Cui, P. Dua, A. I. Pogue, S. Bhattacharjee, and W. J. Lukiw, “Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells,” Neuroscience Letters, vol. 499, no. 2, pp. 109–113, 2011.
[22] D. M. Basso, M. S. Beattie, and J. C. Bresnahan, “A sensitive and reliable locomotor rating scale for open field testing in rats,” Journal of Neurotrauma, vol. 12, no. 1, pp. 1–21, 1995.
[23] W. J. Lukiw, P. Dua, A. I. Pogue, C. Eicken, and J. M. Hill, “Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic creutzfeldt-jakob disease (sCJD) and gerstmann-straussler-scheinker (GSS) syndrome,” Journal of Toxicology and Environmental Health—Part A, vol. 74, no. 22–24, pp. 1460–1468, 2011.
disease (sCJD) and gerstmann-straussler-scheinker (GSS) syndrome,” Journal of Toxicology and Environmental Health–Part A: Current Issues, vol. 74, no. 22–24, pp. 1460–1468, 2011.

[25] J. H. Paik, J.-Y. Jang, Y. K. Jeon et al., “MicroRNA-146a down-regulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma,” Clinical Cancer Research, vol. 17, no. 14, pp. 4761–4771, 2011.

[26] S. Li, Y. Yue, W. Xu, and S. Xiong, “MicroRNA-146a represses mycobacteria-induced inflammatory response and facilitates bacterial replication via targeting IRAK-1 and TRAF-6,” PLoS ONE, vol. 8, no. 12. Article ID e81438, 2013.

[27] X. Li, G. Gibson, J.-S. Kim et al., “MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis,” Gene, vol. 480, no. 1-2, pp. 34–41, 2011.

[28] Y.-F. Xie, R. Shu, S.-Y. Jiang, D.-L. Liu, J. Ni, and X.-L. Zhang, “MicroRNA-146 inhibits pro-inflammatory cytokine secretion through IL-1 receptor-associated kinase 1 in human gingival fibroblasts,” Journal of Inflammation, vol. 10, no. 1, article 20, 2013.

[29] T. Nakasa, S. Miyaki, A. Okubo et al., “Expression of microRNA-146 in rheumatoid arthritis synovial tissue,” Arthritis & Rheumatism, vol. 58, no. 5, pp. 1284–1292, 2008.

[30] Y. Xie, R. Shu, S. Jiang et al., “miRNA-146 negatively regulates the production of pro-inflammatory cytokines via NF-κB signalling in human gingival fibroblasts,” Journal of Inflammation, vol. 11, no. 1, article 38, 1 page, 2014.

[31] X. Ma, L. E. Becker Buscaglia, J. R. Barker, and Y. Li, “MicroRNAs in NF-κB signaling,” Journal of Molecular Cell Biology, vol. 3, no. 3, pp. 159–166, 2011.